RUNX1 and hematopoietic and lymphoid cell neoplasm: Based on the data we present here, on our previously published work [17], [48], [49], and on the work by Hoyt et al [3], we would like to propose a novel role of EVI1 as a global player in DNA modification, rather than solely as a lineage- or tissue-specific oncogene, which acts as a co-factor in protein complexes that regulate DNA and chromatin modifications both during normal embryogenesis and in solid and hematopoietic cancers when the gene is inappropriately activated.